A Phase 2 interventional study of MK-1602 and Placebo-matching MK-1602 in Migraine, sponsored by Allergan. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-01-08.
Sponsored by Allergan (part of AbbVie) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing ubrogepant in Migraine Disorders — 2 open to participants now, 4 under way, 3 of them phase 3. ubrogepant · Migraine Disorders.
Among the 14 studies testing ubrogepant in Migraine Disorders, this one is the 6th largest by enrollment, is one of 2 that started in 2012, is one of 2 in phase 2, and was the 1st registered.
1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →2 of the 14 studies testing ubrogepant in Migraine Disorders are open now, in 2 countries. Recruiting first, the newest first:
AbbVie · Sites in United States, Puerto Rico
Ages 6–17
AbbVie · Sites in United States, Puerto Rico
Ages 6–17
By country, each count listing its studies:
ubrogepant: first FDA approval 2019 (UBRELVY). What it is approved for, and how studies give it, is on its page →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 834 is above the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Median enrollment 507 across the 14 interventional studies. Of the 10 that completed or were terminated, 8 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 14 have an industry lead sponsor. The 4 most frequent:
This study is registered under Allergan, one of the names counted as AbbVie. Under that name alone:
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
55 studies in Migraine Disorders by AbbVie: 9 open now, 13 under way, 7 of them phase 3. Of 40 finished, 32 (80%) have results posted.
Among the 55 studies in Migraine Disorders by AbbVie, this one is the 9th largest by enrollment of the 41 interventional ones that give a count, is one of 6 that started in 2012, is one of 3 in phase 2, and was the 6th registered.
AbbVie’s Migraine Disorders studies by the year they started, since 2006.
2 of the studies testing ubrogepant in Migraine Disorders that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05125302Phase 3AbbVieStudy to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | 2027-05 |
| NCT06417775Phase 3AbbVieStudy of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | 2027-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies testing ubrogepant in Migraine Disorders, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 55 in Migraine Disorders:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the effectiveness, safety and tolerability of a range of doses of MK-1602 versus placebo in the treatment of acute migraine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
the two months prior to screening
reproductive potential with a screening serum β-human chorionic gonadotropin (β-hCG) level consistent with a not-pregnant state, and who agrees to use acceptable
Exclusion Criteria:
resolve spontaneously in less than two hours
has changed during the 3 months prior to screening and will not be changed
during the study
in response to 3 or more classes of drugs (prescription and over-the-counter)
surgery or banding), or presence of a disease that causes malabsorption
weeks of study, or intent to donate blood products or receive
blood products within 30 days of screening and throughout study
study
in a study with an compound or device
analgesic for migraine relief
attack within the past 2 months
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MK-1602 1 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.
Drug: MK-1602 · Drug: Rescue medication
MK-1602 10 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.
Drug: MK-1602 · Drug: Rescue medication
MK-1602 25 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.
Drug: MK-1602 · Drug: Rescue medication
MK-1602 50 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.
Drug: MK-1602 · Drug: Rescue medication
MK-1602 100 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.
Drug: MK-1602 · Drug: Rescue medication
Placebo-matching MK-1602 single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.
Drug: Placebo-matching MK-1602 · Drug: Rescue medication
Single 1, 10, 25, 50 or 100 mg dose of MK-1602 taken at onset of migraine of moderate or severe intensity. Dosage form is film coated tablet for oral administration. Dose is provided to participants as a blinded bottle of tablets packaged to achieve the various MK-1602 dose levels to be studied. Participants will be instructed to take all study medication from the bottle when they treat their migraine headache.
Single administration of placebo-matching MK-1602 taken at onset of migraine of moderate or severe intensity. Dosage form is film coated tablet for oral administration. Dose is provided to participants as a blinded bottle of tablets packaged to achieve placebo study medication. Participants will be instructed to take all study medication from the bottle when they treat their migraine headache.
If moderate or severe migraine headache pain continues 2 hours after dose of study medication or if migraine headache comes back within 48 hours, Participants will be allowed to take their own rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs \[NSAIDs\]), anti-emetics, triptans or other medication not explicitly excluded.
Percentage of Participants Reporting Pain Freedom (PF) at 2 Hours Post-Dose
PF was defined as a reduction in headache severity from Grade 2 or 3 at Baseline to Grade 0. Headache severity was reported by the participant using a 4-point scale where: 0=no pain, 1=mild pain, 2=moderate pain and 3=severe pain.
Time frame: 2 hours post-dose
Percentage of Participants Reporting Pain Relief (PR) at 2 Hours Post-Dose
PR was defined as a reduction of a moderate or severe migraine headache (Grade 2 or 3) at Baseline to a mild headache or no headache (Grade 1 or 0) 2 hours post-dose. Headache severity was reported by the participant using a 4-point scale where: 0=no pain, 1=mild pain, 2=moderate pain and 3=severe pain.
Time frame: 2 hours post-dose
Number of Participants With One or More Adverse Events Within 48 Hours Post-Dose
An AE is any unfavorable and unintended change in the structure (signs), function (symptoms), or chemistry (laboratory data) of the body temporally associated with any use of a sponsor product, whether or not considered related to the use of the product.
Time frame: Up to 48 hours post-dose
Number of Participants With One or More Adverse Events Within 14 Days Post-Dose
An AE is any unfavorable and unintended change in the structure (signs), function (symptoms), or chemistry (laboratory data) of the body temporally associated with any use of a sponsor product, whether or not considered related to the use of the product.
Time frame: Up to 14 days post-dose
Number of Participants Who Discontinued From Study Due to Adverse Events
Time frame: Up to 5 weeks post-dose
Percentage of Participants Reporting Absence of Phonophobia at 2 Hours Post-Dose
Phonophobia is sensitivity to loud sounds.
Time frame: 2 hours post-dose
Percentage of Participant Reporting Absence of Photophobia at 2 Hours Post-Dose
Photophobia is sensitivity to bright light.
Time frame: 2 hours post-dose
Percentage of Participants Reporting Absence of Nausea at 2 Hours Post-Dose
Time frame: 2 hours post-dose
Percentage of Participants Reporting Sustained Pain Freedom (SPF) 2-24 Hours Post-Dose
SPF was defined as PF at 2 hours post-dose, with no administration of any rescue medication and with no occurrence of a mild/moderate/severe headache during the 24 hour period after dosing with study medication.
Time frame: 2-24 hours post-dose
Percentage of Participants Reporting SPF 2-48 Hours Post-Dose
SPF was defined as PF at 2 hours post-dose, with no administration of any rescue medication and with no occurrence of a mild/moderate/severe headache during the 48 hour period after dosing with study medication.
Time frame: 2-48 hours post-dose
Percentage of Participants Reporting Sustained Pain Relief (SPR) 2-24 Hours Post-Dose
SPR was defined as PR at 2 hours post-dose, with no administration of any rescue medication and with no occurrence of a moderate/severe headache during the 24 hour period after dosing with study medication.
Time frame: 2-24 hours post-dose
Percentage of Participants Reporting SPR 2-48 Hours Post-Dose
SPR was defined as PR at 2 hours post-dose, with no administration of any rescue medication and with no occurrence of a moderate/severe headache during the 48 hour period after dosing with study medication.
Time frame: 2-48 hours post-dose
Percentage of Participants Reporting Total Migraine Freedom (TMF) at 2 Hours Post-Dose
TMF at 2 hours post dose was defined as PF with no photophobia, phonophobia, nausea, or vomiting at 2 hours post-dose.
Time frame: 2 hours post-dose
Percentage of Participants Reporting TMF at 2-24 Hours Post-Dose
TMF at 2-24 hours post-dose was defined as SPF with no photophobia, phonophobia, nausea, or vomiting during the 2 to 24 hour period after dosing with study medication.
Time frame: 2-24 hours post-dose
Percentage of Participants Reporting TMF at 2-48 Hours Post-Dose
TMF at 2-48 hours post-dose was defined as SPF with no photophobia, phonophobia, nausea, or vomiting during the 2 to 48 hour period after dosing with study medication.
Time frame: 2-48 hours post-dose
| Milestone | Placebo | MK-1602 1 mg | MK-1602 10 mg | MK-1602 25 mg | MK-1602 50 mg | MK-1602 100 mg |
|---|---|---|---|---|---|---|
| Started | 139 | 138 | 139 | 139 | 139 | 140 |
| Completed | 110 | 104 | 106 | 101 | 104 | 102 |
| Not completed | 29 | 34 | 33 | 38 | 35 | 38 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 3 | 2 | 2 | 5 | 0 | 1 |
| Withdrew: Lost to follow-up | 5 | 7 | 4 | 8 | 4 | 2 |
| Withdrew: Study terminated by sponsor | 4 | 6 | 8 | 8 | 9 | 11 |
| Withdrew: Physician decision | 8 | 8 | 9 | 4 | 7 | 6 |
| Withdrew: Lack of qualifying event | 9 | 11 | 10 | 11 | 15 | 18 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 1 | 0 | 0 |
PF was defined as a reduction in headache severity from Grade 2 or 3 at Baseline to Grade 0. Headache severity was reported by the participant using a 4-point scale where: 0=no pain, 1=mild pain, 2=moderate pain and 3=severe pain.
| percentage of participants | Placebo | MK-1602 1 mg | MK-1602 10 mg | MK-1602 25 mg | MK-1602 50 mg | MK-1602 100 mg |
|---|---|---|---|---|---|---|
| Percentage of Participants Reporting Pain Freedom (PF) at 2 Hours Post-Dose | 8.9 (4.4 to 15.8) | 5.6 (2.1 to 11.8) | 14.8 (8.7 to 22.9) | 21.4 (13.9 to 30.5) | 21.0 (13.6 to 30.0) | 25.5 (17.4 to 35.1) |
PR was defined as a reduction of a moderate or severe migraine headache (Grade 2 or 3) at Baseline to a mild headache or no headache (Grade 1 or 0) 2 hours post-dose. Headache severity was reported by the participant using a 4-point scale where: 0=no pain, 1=mild pain, 2=moderate pain and 3=severe pain.
| percentage of participants | Placebo | MK-1602 1 mg | MK-1602 10 mg | MK-1602 25 mg | MK-1602 50 mg | MK-1602 100 mg |
|---|---|---|---|---|---|---|
| Percentage of Participants Reporting Pain Relief (PR) at 2 Hours Post-Dose | 44.6 (35.2 to 54.3) | 37.4 (28.2 to 47.3) | 52.8 (42.9 to 62.5) | 53.4 (43.3 to 63.3) | 57.1 (47.1 to 66.8) | 58.8 (48.6 to 68.5) |
An AE is any unfavorable and unintended change in the structure (signs), function (symptoms), or chemistry (laboratory data) of the body temporally associated with any use of a sponsor product, whether or not considered related to the use of the product.
| participants | Placebo | MK-1602 1 mg | MK-1602 10 mg | MK-1602 25 mg | MK-1602 50 mg | MK-1602 100 mg |
|---|---|---|---|---|---|---|
| Number of Participants With One or More Adverse Events Within 48 Hours Post-Dose | 28 | 33 | 29 | 21 | 23 | 30 |
An AE is any unfavorable and unintended change in the structure (signs), function (symptoms), or chemistry (laboratory data) of the body temporally associated with any use of a sponsor product, whether or not considered related to the use of the product.
| participants | Placebo | MK-1602 1 mg | MK-1602 10 mg | MK-1602 25 mg | MK-1602 50 mg | MK-1602 100 mg |
|---|---|---|---|---|---|---|
| Number of Participants With One or More Adverse Events Within 14 Days Post-Dose | 33 | 37 | 32 | 24 | 30 | 32 |
| participants | Placebo | MK-1602 1 mg | MK-1602 10 mg | MK-1602 25 mg | MK-1602 50 mg | MK-1602 100 mg |
|---|---|---|---|---|---|---|
| Number of Participants Who Discontinued From Study Due to Adverse Events | 0 | 0 | 0 | 0 | 0 | 0 |
Phonophobia is sensitivity to loud sounds.
| percentage of participants | Placebo | MK-1602 1 mg | MK-1602 10 mg | MK-1602 25 mg | MK-1602 50 mg | MK-1602 100 mg |
|---|---|---|---|---|---|---|
| Percentage of Participants Reporting Absence of Phonophobia at 2 Hours Post-Dose | 42.0 (32.7 to 51.7) | 45.8 (36.1 to 55.7) | 49.1 (39.3 to 58.9) | 55.3 (45.2 to 65.1) | 56.2 (46.2 to 65.9) | 60.8 (50.6 to 70.3) |
Photophobia is sensitivity to bright light.
| percentage of participants | Placebo | MK-1602 1 mg | MK-1602 10 mg | MK-1602 25 mg | MK-1602 50 mg | MK-1602 100 mg |
|---|---|---|---|---|---|---|
| Percentage of Participant Reporting Absence of Photophobia at 2 Hours Post-Dose | 30.4 (22.0 to 39.8) | 37.4 (28.2 to 47.3) | 43.5 (34.0 to 53.4) | 39.8 (30.3 to 49.9) | 47.6 (37.8 to 57.6) | 54.9 (44.7 to 64.8) |
| percentage of participants | Placebo | MK-1602 1 mg | MK-1602 10 mg | MK-1602 25 mg | MK-1602 50 mg | MK-1602 100 mg |
|---|---|---|---|---|---|---|
| Percentage of Participants Reporting Absence of Nausea at 2 Hours Post-Dose | 62.5 (52.9 to 71.5) | 59.8 (49.9 to 69.2) | 67.6 (57.9 to 76.3) | 73.8 (64.2 to 82.0) | 68.6 (58.8 to 77.3) | 70.6 (60.7 to 79.2) |
SPF was defined as PF at 2 hours post-dose, with no administration of any rescue medication and with no occurrence of a mild/moderate/severe headache during the 24 hour period after dosing with study medication.
| percentage of participants | Placebo | MK-1602 1 mg | MK-1602 10 mg | MK-1602 25 mg | MK-1602 50 mg | MK-1602 100 mg |
|---|---|---|---|---|---|---|
| Percentage of Participants Reporting Sustained Pain Freedom (SPF) 2-24 Hours Post-Dose | 6.2 (2.5 to 12.3) | 4.7 (1.5 to 10.6) | 9.3 (4.5 to 16.4) | 14.6 (8.4 to 22.9) | 15.1 (8.9 to 23.4) | 21.6 (14.0 to 30.8) |
SPF was defined as PF at 2 hours post-dose, with no administration of any rescue medication and with no occurrence of a mild/moderate/severe headache during the 48 hour period after dosing with study medication.
| percentage of participants | Placebo | MK-1602 1 mg | MK-1602 10 mg | MK-1602 25 mg | MK-1602 50 mg | MK-1602 100 mg |
|---|---|---|---|---|---|---|
| Percentage of Participants Reporting SPF 2-48 Hours Post-Dose | 6.2 (2.5 to 12.3) | 4.7 (1.5 to 10.6) | 9.3 (4.5 to 16.4) | 14.6 (8.4 to 22.9) | 14.2 (8.1 to 22.3) | 20.6 (13.2 to 29.7) |
SPR was defined as PR at 2 hours post-dose, with no administration of any rescue medication and with no occurrence of a moderate/severe headache during the 24 hour period after dosing with study medication.
| percentage of participants | Placebo | MK-1602 1 mg | MK-1602 10 mg | MK-1602 25 mg | MK-1602 50 mg | MK-1602 100 mg |
|---|---|---|---|---|---|---|
| Percentage of Participants Reporting Sustained Pain Relief (SPR) 2-24 Hours Post-Dose | 28.3 (20.2 to 37.6) | 17.8 (11.0 to 26.3) | 36.1 (27.1 to 45.9) | 39.8 (30.3 to 49.9) | 45.7 (36.0 to 55.7) | 46.1 (36.2 to 56.2) |
SPR was defined as PR at 2 hours post-dose, with no administration of any rescue medication and with no occurrence of a moderate/severe headache during the 48 hour period after dosing with study medication.
| percentage of participants | Placebo | MK-1602 1 mg | MK-1602 10 mg | MK-1602 25 mg | MK-1602 50 mg | MK-1602 100 mg |
|---|---|---|---|---|---|---|
| Percentage of Participants Reporting SPR 2-48 Hours Post-Dose | 25.0 (17.3 to 34.1) | 17.0 (10.4 to 25.5) | 32.4 (23.7 to 42.1) | 37.9 (28.5 to 48.0) | 42.9 (33.2 to 52.9) | 43.1 (33.4 to 53.3) |
TMF at 2 hours post dose was defined as PF with no photophobia, phonophobia, nausea, or vomiting at 2 hours post-dose.
| percentage of participants | Placebo | MK-1602 1 mg | MK-1602 10 mg | MK-1602 25 mg | MK-1602 50 mg | MK-1602 100 mg |
|---|---|---|---|---|---|---|
| Percentage of Participants Reporting Total Migraine Freedom (TMF) at 2 Hours Post-Dose | 8.0 (3.7 to 14.7) | 5.6 (2.1 to 11.8) | 13.9 (8.0 to 21.9) | 20.4 (13.1 to 29.5) | 20.0 (12.8 to 28.9) | 23.5 (15.7 to 33.0) |
TMF at 2-24 hours post-dose was defined as SPF with no photophobia, phonophobia, nausea, or vomiting during the 2 to 24 hour period after dosing with study medication.
| percentage of participants | Placebo | MK-1602 1 mg | MK-1602 10 mg | MK-1602 25 mg | MK-1602 50 mg | MK-1602 100 mg |
|---|---|---|---|---|---|---|
| Percentage of Participants Reporting TMF at 2-24 Hours Post-Dose | 5.3 (2.0 to 11.2) | 4.7 (1.5 to 10.6) | 9.3 (4.5 to 16.4) | 12.6 (6.9 to 20.6) | 14.2 (8.1 to 22.3) | 20.6 (13.2 to 29.7) |
TMF at 2-48 hours post-dose was defined as SPF with no photophobia, phonophobia, nausea, or vomiting during the 2 to 48 hour period after dosing with study medication.
| percentage of participants | Placebo | MK-1602 1 mg | MK-1602 10 mg | MK-1602 25 mg | MK-1602 50 mg | MK-1602 100 mg |
|---|---|---|---|---|---|---|
| Percentage of Participants Reporting TMF at 2-48 Hours Post-Dose | 5.3 (2.0 to 11.2) | 4.7 (1.5 to 10.6) | 9.3 (4.5 to 16.4) | 12.6 (6.9 to 20.6) | 13.2 (7.4 to 21.2) | 19.6 (12.4 to 28.6) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/113 (0%) | 15/113 (13.3%) |
| MK-1602 1 mg | — | 0/107 (0%) | 22/107 (20.6%) |
| MK-1602 10 mg | — | 0/108 (0%) | 13/108 (12%) |
| MK-1602 25 mg | — | 0/104 (0%) | 15/104 (14.4%) |
| MK-1602 50 mg | — | 1/106 (0.9%) | 14/106 (13.2%) |
| MK-1602 100 mg | — | 0/102 (0%) | 17/102 (16.7%) |
| Event | Placebo | MK-1602 1 mg | MK-1602 10 mg | MK-1602 25 mg | MK-1602 50 mg | MK-1602 100 mg |
|---|---|---|---|---|---|---|
| MyoclonusNervous system disorders | 0/113 | 0/107 | 0/108 | 0/104 | 1/106 | 0/102 |
| Event | Placebo | MK-1602 1 mg | MK-1602 10 mg | MK-1602 25 mg | MK-1602 50 mg | MK-1602 100 mg |
|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 4/113 | 7/107 | 4/108 | 6/104 | 8/106 | 7/102 |
| Dry mouthGastrointestinal disorders | 4/113 | 8/107 | 2/108 | 3/104 | 4/106 | 5/102 |
| DizzinessNervous system disorders | 1/113 | 8/107 | 5/108 | 3/104 | 2/106 | 6/102 |
| SomnolenceNervous system disorders | 6/113 | 5/107 | 4/108 | 5/104 | 3/106 | 4/102 |
All Subjects as Treated Population included all randomized participants who received at least 1 dose of study treatment.
| Age, Continuous(years) | Placebo | MK-1602 1 mg | MK-1602 10 mg | MK-1602 25 mg | MK-1602 50 mg | MK-1602 100 mg | Total |
|---|---|---|---|---|---|---|---|
| Mean | 40.5 ± 11.7 | 39.6 ± 10.7 | 41.1 ± 10.9 | 41.4 ± 11.5 | 40.7 ± 12.3 | 41.9 ± 11.0 | 40.8 ± 11.4 |
| Age, Customized(participants) | Placebo | MK-1602 1 mg | MK-1602 10 mg | MK-1602 25 mg | MK-1602 50 mg | MK-1602 100 mg | Total |
|---|---|---|---|---|---|---|---|
| < 20 years | 1 | 1 | 0 | 2 | 2 | 0 | 6 |
| 20 to 29 years | 18 | 21 | 19 | 13 | 19 | 16 | 106 |
| 30 to 39 years | 42 | 29 | 28 | 32 | 32 | 26 | 189 |
| 40 to 49 years | 22 | 36 | 42 | 33 | 23 | 33 | 189 |
| 50 to 59 years | 19 | 17 | 14 | 16 | 21 | 23 | 110 |
| 60 to 64 years | 10 | 2 | 5 | 8 | 9 | 3 | 37 |
| >= 65 years | 1 | 1 | 0 | 0 | 0 | 1 | 3 |
| Sex: Female, Male(Participants) | Placebo | MK-1602 1 mg | MK-1602 10 mg | MK-1602 25 mg | MK-1602 50 mg | MK-1602 100 mg | Total |
|---|---|---|---|---|---|---|---|
| Female | 99 | 95 | 92 | 91 | 92 | 90 | 559 |
| Male | 14 | 12 | 16 | 13 | 14 | 12 | 81 |
No study locations are listed for this record.
Ran from Jul 2012 to primary completion in Dec 2012, 5 months.
Results were first posted in Sep 2016, 3 years 9 months after primary completion.
Of 43 industry-sponsored phase 2 interventional studies under Migraine Disorders, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's 5 months is below that.
Counting every sponsor, half of 73 studies reached it within 15 months; a quarter within 11 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ubrogepant